# Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

> **NCT00352053** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 87 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tenofovir DF
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00352053
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2013-12
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352053, "Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00352053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*